Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 742

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 742
---
 of $ 1,000per share, provide for a cashless exercise feature, and are exercisable for a period of four years from August 19, 2020. The Series C Preferred Stock issuable upon exercise of the Series C Agent Warrants is convertible into shares of common stock in the same manner as each respective underlying series of outstanding Series C Preferred Stock and will be entitled to the same dividend rights as each respective series.

<div align='center'>F-24</div>

The following table sets forth changes in outstanding Series C Agent Warrants:

|                                               |     |     | Balance,June 30, 2023 |     |     | Number ofWarrants 
 Issued            |     |     | Number ofWarrants 
 Exercised         |     |     | Balance,June 30, 2024 |     |     | Exerciseprice$ |
|:----------------------------------------------|:----|:----|----------------------:|:----|:----|:------------------|:----|:----|:------------------|:----|:----|----------------------:|:----|:----|---------------:|
| Issuance of Preferred SeriesC-1Agent Warrants |     |     |                 1,929 |     |     | —                 |     |     | —                 |     |     |                 1,929 |     |     |          58.00 |
| Issuance of Preferred SeriesC-2Agent Warrants |     |     |                   219 |     |     | —                 |     |     | —                 |     |     |                   219 |     |     |          60.70 |
| Issuance of Preferred SeriesC-3Agent Warrants |     |     |                   296 |     |     | —                 |     |     | —                 |     |     |                   296 |     |     |          57.50 |
|                                               |     |     |                 2,444 |     |     | —                 |     |     | —                 |     |     |                 2,444 |     |     |                |

The following table summarizes the Company’s outstanding Series C Agent Warrants as of June 30, 2024:

| Series C Agent Warrants |     | Number |       |     | Conversionprice$ |       |     | Number ofconversionshares(in thousands) |    |     | Cumulativecommonstockdividends(in thousands)